Unibest

Pharmaceutical intermediates

Tovorafenib Intermediates

3 pharmaceutical intermediates for Tovorafenib. Indication: Glioma.

Submit a ProjectAll intermediates

About Tovorafenib

Originator
Sunesis Pharmaceuticals Inc
Indication
Glioma
Approved Date
04/23/2024
NCE Patent
04/23/2029
DS/DP
08/04/2031

Available intermediates

3 intermediates currently listed for Tovorafenib. Request specifications, documentation or a quotation for any item below.

Tovorafenib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
4-Chloro-alpha,alpha,alpha-trifluoro-m-toluidine320-51-4//
6-aMino-5-chloropyriMidine-4-carboxylic acid914916-98-6//
2-acetylthiazole-5-carboxylic acid1095824-76-2//

Other programs under T

Tazemetostat HydrobromideTazobactam SodiumTegoprazanTenapanor HydrochlorideTeneligliptinTetrabenazineTezacaftorTianeptine sodium salt

Building toward Tovorafenib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

Submit a Project Talk to the team

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here

Contact Us →